Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat
This double-blind, placebo-controlled study (n=40) investigates the effect of DMT-harmine ('pharmahuasca') on meditative states during a 3-day retreat with experienced meditators. It finds that participants who received DMT-harmine reported greater mystical-type experiences, non-dual awareness, and emotional breakthrough during acute effects, as well as greater psychological insight one day later, compared to the placebo group.
Authors
- Milan Scheidegger
- Dominik Dornbierer
- Anne Aicher
Published
Abstract
Background
In recent years, both meditation and psychedelics have attracted rapidly increasing scientific interest. While the current state of evidence suggests the promising potential of psychedelics, such as psilocybin, to enhance meditative training, it remains equivocal whether these effects are specifically bound to psilocybin or if other classical psychedelics might show synergistic effects with meditation practice. One particularly promising candidate is N,N-dimethyltryptamine (DMT), an active ingredient of ayahuasca.
Aim
This study aims to investigate the effect of the psychedelic substance DMT, combined with the monoamine oxidase inhibitor harmine (DMT-harmine), on meditative states, compared to meditation with a placebo.
Method
Forty experienced meditators (18 females and 22 males) participated in a double-blind, placebo-controlled study over a 3-day meditation retreat, receiving either placebo or DMT-harmine. Participants’ levels of mindfulness, compassion, insight, and transcendence were assessed before, during, and after the meditation group retreat, using psychometric questionnaires.
Results
Compared to meditation with a placebo, meditators who received DMT and harmine self-attributed greater levels of mystical-type experiences, non-dual awareness, and emotional breakthrough during the acute substance effects and, when corrected for baseline differences, greater psychological insight 1 day later. Mindfulness and compassion were not significantly different in the DMT-harmine group compared to placebo. At 1-month follow-up, the meditators who received DMT and harmine rated their experience as significantly more personally meaningful, spiritually significant, and well-being-enhancing than the meditators who received placebo.
Conclusion
Investigating the impact of DMT-harmine on meditators in a naturalistic mindfulness group retreat, this placebo-controlled study highlights the specific effects of psychedelics during meditation.
Research Summary of 'Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat'
Introduction
Both meditation and psychedelic substances have attracted substantially increased scientific attention over recent years, each accumulating evidence for benefits to mental health and psychological wellbeing through largely distinct but potentially complementary mechanisms. Meditation can be understood across four core dimensions of flourishing — awareness, connection, insight, and purpose — and its benefits have been consistently demonstrated across randomised controlled studies. Psychedelic substances, similarly, have shown promising effects on well-being, existential distress, and depression in clinical trials, with hypothesised mechanisms including the induction of mystical experiences, enhanced psychological insight, and neuroplasticity. Despite theoretical synergies and anecdotal overlap in contemplative traditions, rigorous controlled research into the combination of psychedelics and meditation has been limited — and, prior to the present investigation, confined to psilocybin. This study aimed to conduct the first randomised placebo-controlled trial of a DMT-harmine formulation (an ayahuasca analogue) during a structured mindfulness retreat, examining effects on mindfulness, compassion, insight, and transcendence in intermediate meditation practitioners.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Meling, D., Egger, K., Aicher, H. D., Jareño Redondo, J., Mueller, J., Dornbierer, J., Temperli, E., Vasella, E. A., Caflisch, L., Pfeiffer, D. J., Schlomberg, J. T., Smallridge, J. W., Dornbierer, D. A., & Scheidegger, M. (2024). Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat. Journal of Psychopharmacology, 38(10), 897-910. https://doi.org/10.1177/02698811241282637
References (39)
Papers cited by this study that are also in Blossom
Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Human Psychopharmacology (2021)
Dornbierer, D. A., Marten, L., Mueller, J. et al. · Frontiers in Pharmacology (2023)
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C. et al. · Journal of Psychopharmacology (2016)
Show all 39 referencesShow fewer
Gandy, S., Bonnelle, V., Jacobs, E. et al. · Drug Science Policy and Law (2022)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Goldberg, S. B., Shechet, B., Nicholas, C. R. et al. · Psychological Medicine (2020)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Hartogsohn, I. · Journal of Psychopharmacology (2016)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Lawrence, D. W., Sharma, B., Griffiths, R. R. et al. · Journal of Psychoactive Drugs (2021)
Meling, D., Ehrenkra, R., Nayak, S. et al. · Psychoactives (2024)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)
Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M. et al. · Frontiers in Psychology (2022)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Simonsson, A., Simonsson, O., Chambers, R. et al. · Mindfulness (2023)
Simonsson, O., Goldberg, S. B. · Journal of Psychoactive Drugs (2022)
Berit, S., Meling, D., Hirsch-Hoffmann, M. et al. · Scientific Reports (2024)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Cited By (2)
Papers in Blossom that reference this study
Egger, K., Meling, D., Polat, F. et al. · Imaging Neuroscience (2025)
Aicher, H. D., Wicki, I. A., Meling, D. et al. · Journal of Psychopharmacology (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.